US4983392A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bioadhesive compositions and methods of treatment therewith
Assignee: Juniper Pharmaceuticals Inc
•
Filing: 1988-12-20
•
Granted: 1991-01-08
•
Expires: 2008-12-20
Abstract
Abstract A controlled release treatment composition and method of use are disclosed. The composition includes a bioadhesive and an effective amount of a treating agent. The bioadhesive is a water-swellable, but water-insoluble, fibrous, cross-linked carboxy-functional polymer containing (a) a plurality of repeating units of which at least about 80 percent contain at least one carboxyl functionality, and (b) about 0.05 to about 1.5 percent cross-linking agent substantially free from polyalkenyl polyether.
Inventors
- 👤 Joseph R. Robinson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 22:20
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0053; A61K9/0065; A61K9/48; A61K9/4808; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5026; A61K9/70; A61K9/7007
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
103 words
A controlled release ophthalmic treatment composition including a bioadhesive and an effective amount of an ophthalmic treating agent, said bioadhesive comprising a water-swellable, but water-insoluble, particular cross-linked carboxyl-functional polymer having particles sized so that visual impairment is substantially minimized when said composition is contacted with a mucous membrane of the eye, said polymer containing (a) a plurality of repeating units of which at least about 80 percent contain at least the carboxyl functionally, and (b) about 0.05 to about 1.5 percent cross-linking agent substantially free from polyalkylenyl polyether, said percentages being based upon the weights of the unpolymerized repeating unit cross-linking agent, respectively.
Claim 2
Dependent Claim
103 words
A controlled release ophthalmic treatment composition including a bioadhesive and an effective amount of an ophthalmic treating agent, said bioadhesive comprising a water-swellable, but water-insoluble, particular cross-linked carboxyl-functional polymer having particles sized so that visual impairment is substantially minimized when said composition is contacted with a mucous membrane of the eye, said polymer containing (a) a plurality of repeating units of which at least about 80 percent contain at least the carboxyl functionally, and (b) about 0.05 to about 1.5 percent cross-linking agent substantially free from polyalkylenyl polyether, said percentages being based upon the weights of the unpolymerized repeating unit cross-linking agent, respectively.
Claim 3
Dependent Claim
23 words
A controller release ophthalmic treatment composition as recited in claim 1 wherein said bioadhesive and said treating agent are intimately admixed substantially uniformly.
Claim 4
Dependent Claim
28 words
A controlled release ophthalmic treatment composition as recited in claim 1 wherein at least about 90 percent of said polymer repeating units contain at least one carboxyl functionality.
Claim 5
Dependent Claim
28 words
A controlled release ophthalmic treatment composition as recited in claim 1 wherein at least about 95 percent of said polymer repeating units contain at least one carboxyl functionality.
Claim 6
Dependent Claim
27 words
A controlled release ophthalmic treatment composition as recited in claim 1 wherein said polymer contains about 0.1 to about 1 percent by weight of polymerized cross-linking agent.
Claim 7
Dependent Claim
21 words
A controlled release ophthalmic treatment composition as recited in claim 1 wherein said carboxyl functionality is provided by polymerized acrylic acid.
Claim 8
Dependent Claim
48 words
A controlled release ophthalmic treatment composition as recited in claim 1 wherein at least about 95 percent of said polymer repeating units contain at least one carboxyl functionality provided by acrylic acid, and said polymer contains about 0.1 to about 1 percent by weight of polymerized cross-linking agent.
Claim 9
Dependent Claim
17 words
A controlled release ophthalmic treatment composition as recited in claim 7 wherein said cross-linking agent is 3,4-dihydroxy-1,5-hexadiene.
Claim 10
Dependent Claim
18 words
A controlled release ophthalmic treatment composition as recited in claim 7 wherein said cross-linking agent is divinyl benzene.
Claim 11
Dependent Claim
17 words
A controlled release ophthalmic treatment composition as recited in claim 7 wherein said cross-linking agent is 2,5-dimethyl-1,5-hexadiene.
Claim 12
Dependent Claim
24 words
A controlled release ophthalmic treatment composition as recited in any one of claims 1-10, inclusive, wherein said ophthalmic treating agent constitutes an anti-inflammatory agent.
Claim 13
Dependent Claim
17 words
A controlled release opthahalmic treatment composition as recited in claim 11 wherein said anti-inflammatory agent is fluorometholone.
References Cited (Backward Citations)
US2798053A
Cited
US2923692A
Cited
US2810716A
Cited
US3121043A
Cited
US3158538A
Cited
US3202577A
Cited
US3297664A
Cited
US3390050A
Cited
US3734097A
Cited
US3797494A
Cited
US3962414A
Cited
US3811444A
Cited
US4450150A
Cited
US4014987A
Cited
US4192827A
Cited
US3958122A
Cited
US4060084A
Cited
US4271143A
Cited
US4230687A
Cited
US4292299A
Cited
US4226848A
Cited
US4359483A
Cited
US4553973A
Cited
US4478818A
Cited
US4548990A
Cited
US4615697A
Cited
US4608048A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-01-07 | 1994-07-09 | 1995-01-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-01-07 | 1998-07-09 | 1999-01-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-01-07 | 2002-07-09 | 2003-01-08 | $7700.00 | Window Closed / Lapsed |